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estimate survival in patients with colorectal cancer: cohort study
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ABSTRACT
ObjeCtive
To develop and externally validate risk prediction 
equations to estimate absolute and conditional 
survival in patients with colorectal cancer. 
Design
Cohort study.
setting
General practices in England providing data for the 
QResearch database linked to the national cancer registry.
PartiCiPants
44 145 patients aged 15-99 with colorectal cancer from 
947 practices to derive the equations. The equations 
were validated in 15 214 patients with colorectal cancer 
from 305 different QResearch practices and 437 821 
patients with colorectal cancer from the national 
cancer registry.
Main OutCOMe Measures
The primary outcome was all cause mortality and 
secondary outcome was colorectal cancer mortality.
MethODs
Cause specific hazards models were used to predict 
risks of colorectal cancer mortality and other cause 
mortality accounting for competing risks, and these risk 
estimates were combined to obtain risks of all cause 
mortality. Separate equations were derived for men and 
women. Several variables were tested: age, ethnicity, 
deprivation score, cancer stage, cancer grade, surgery, 
chemotherapy, radiotherapy, smoking status, alcohol 
consumption, body mass index, family history of bowel 
cancer, anaemia, liver function test result, 
comorbidities, use of statins, use of aspirin, clinical 
values for anaemia, and platelet count. Measures of 
calibration and discrimination were determined in both 
validation cohorts at 1, 5, and 10 years.
results
The final models included the following variables in 
men and women: age, deprivation score, cancer stage, 
cancer grade, smoking status, colorectal surgery, 
chemotherapy, family history of bowel cancer, raised 
platelet count, abnormal liver function, cardiovascular 
disease, diabetes, chronic renal disease, chronic 
obstructive pulmonary disease, prescribed aspirin at 
diagnosis, and prescribed statins at diagnosis. 
Improved survival in women was associated with 
younger age, earlier stage of cancer, well or moderately 
differentiated cancer grade, colorectal cancer surgery 
(adjusted hazard ratio 0.50), family history of bowel 
cancer (0.62), and prescriptions for statins (0.77) and 
aspirin (0.83) at diagnosis, with comparable results for 
men. The risk equations were well calibrated, with 
predicted risks closely matching observed risks. 
Discrimination was good in men and women in both 
validation cohorts. For example, the five year survival 
equations on the QResearch validation cohort 
explained 45.3% of the variation in time to colorectal 
cancer death for women, the D statistic was 1.86, and 
Harrell’s C statistic was 0.80 (both measures of 
discrimination, indicating that the scores are able to 
distinguish between people with different levels of 
risk). The corresponding results for all cause mortality 
were 42.6%, 1.77, and 0.79.
COnClusiOns
Risk prediction equations were developed and 
validated to estimate overall and conditional survival 
of patients with colorectal cancer accounting for an 
individual’s clinical and demographic characteristics. 
These equations can provide more individualised 
accurate information for patients with colorectal 
cancer to inform decision making and follow-up.
Introduction
Traditional estimates of cancer survival provide import-
ant information for guidelines, planning treatment, 
follow-up, and ongoing surveillance for different types 
of cancer. Relative survival estimates are traditionally 
used to cancel out changes in competing causes of 
death so that changes in prevention and treatment 
strategies can be compared over time and between pop-
ulations.1  The relative net survival essentially removes 
the competing cause of death, comparing survival in 
patients with cancer with the expected survival in peo-
ple without cancer. Relative survival estimates are usu-
ally based on analyses of cancer registry data alone and 
presented as a series of tables taking account of one or 
two factors (eg, the patient’s age and sex, or the stage of 
cancer at diagnosis).2 While such estimates are useful 
for researchers and policy makers, they are less  relevant 
for patients and clinicians, who tend to be interested in 
WhAT IS AlReAdy knoWn on ThIS TopIC
Realistic estimates of overall survival are important for patients with a diagnosis of 
colorectal cancer who need to make decisions about the risks and benefits of 
surgery, chemotherapy, radiotherapy, or palliative care
There is a lack of robust information on survival that takes account of patient 
characteristics and the likely effect of different treatments
Prognostic models that include more variables tend to produce more accurate 
predictions than those simply based on stage of cancer at diagnosis
WhAT ThIS STudy AddS
New prognostic models for colorectal cancer that predict both overall survival and 
colorectal mortality were developed and validated
The models include the facility to update the survival estimates conditional on the 
number of years of survival since diagnosis
Compared with other models, they predict survival over a longer period and have 
better discrimination
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individualised absolute survival to support treatment 
decisions and make informed and meaningful choices.
Several prognostic models exist, which predict over-
all mortality or survival for colorectal cancer.3-6 
Although these models incorporate additional clinical 
variables and show improved performance compared 
with the Tumour Nodes Metastases (TNM) system, they 
tend to be limited to specific patient groups (such as 
those with stage 3 disease5  or those undergoing cura-
tive intent surgery6 ), be based on selected populations 
of patients recruited to clinical trials5 6  or attending 
 specialist centres, and have relatively poor 
 discrimination5 6  or are not published.4  None of these 
models can be applied to all patients with colorectal 
cancer, incorporate family history or specific comorbid-
ities, predict survival over periods longer than five 
years, or update predictions based on the number of 
years survived since diagnosis.4-6
Realistic estimates of overall survival are particu-
larly important for patients with a diagnosis of cancer 
who need to make decisions about the risks and bene-
fits of active versus supportive treatment (eg, whether 
to have surgery, chemotherapy, radiotherapy, or palli-
ative care).7  Current evidence suggests that issues 
around survival are only discussed properly in approx-
imately 30% of cases.8  This may reflect a lack of robust 
information on survival, which takes account of 
patient characteristics and the likely effect of different 
treatments.9
Therefore, we decided to develop and externally val-
idate a set of prediction equations to quantify absolute 
survival for patients with colorectal cancer. We 
accounted for other clinical factors available through 
routine linkage of cancer registry data to primary care 
electronic health records. We decided to include esti-
mates of conditional survival since this provides a more 
relevant measure of survival among those surviving the 
first year, especially when the initial prognosis is poor 
(ie, advanced stage colorectal cancer).10  Such estimates 
can be used to provide better information for patients 
and clinicians to help inform treatment and other life 
decisions.1
Methods
study design and data source
We undertook a cohort study to derive and validate the 
risk equations in a large population of primary care 
patients with colorectal cancer using the UK QResearch 
database (version 41, www.qresearch.org). A second 
external validation was undertaken using a separate 
cohort of patients included on the national cancer reg-
istry. QResearch is a continually updated patient level 
pseudonymised database, with data extending back to 
1989. It includes data from over 1200 general practices 
covering a population of more than 22 million patients, 
collected during the course of routine healthcare. The 
data includes demographic information, smoking sta-
tus, alcohol consumption, diagnoses, prescriptions, 
referrals, laboratory test results, and clinical values. 
QResearch has been used for a wide range of clinical 
research, such as the development and validation of 
risk prediction models,11  including risk of existing but 
undiagnosed cancer12  and future cancers.13
QResearch is linked at individual patient level to 
national cancer registry data supplied by Public Health 
England (PHE) and the mortality register supplied by 
the Office for National Statistics (ONS).1 The mortality 
register includes information on the date of death as 
well as the primary and underlying cause of death. The 
PHE cancer registry currently includes all cancers regis-
tered in England between 1990 and 2014, with follow-up 
for mortality until 31 December 2015. The PHE cancer 
registry includes information on year of birth, age at 
diagnosis, date of death, sex, ethnicity, Townsend 
deprivation fifth, date of cancer diagnosis, binary vari-
ables for cancer treatments such as surgery and chemo-
therapy undertaken within a year of diagnosis, tumour 
location, tumour growth behaviour, cancer grade, can-
cer stage, and whether the cancer diagnosis was only 
present on a death certificate. The PHE cancer registry, 
however, does not include the cause of death or other 
variables such as smoking status, alcohol consump-
tion, body mass index, comorbidities, or prescribed 
drugs.
Cohort selection
We included all QResearch practices using the Egton 
Medical Information Systems (EMIS) for at least one 
year during the study period. We randomly allocated 
three quarters of these practices to the derivation data-
set and the remaining quarter to a validation dataset. In 
both datasets we identified open cohorts of patients 
registered with eligible practices between 1 January 
1998 and 31 December 2014.
inclusion and exclusion criteria
We included patients registered with QResearch with a 
first recorded diagnosis of colorectal cancer on the 
linked cancer registry data between 1 January 1998 and 
31 December 2014. To identify cases of colorectal cancer 
we used ICD-10 (international classification of diseases, 
10th revision) codes (C18, C19, and C20).14-16 The analy-
sis was restricted to patients aged 15 to 99 years at diag-
nosis who had a first diagnosis of colorectal cancer 
during the period of registration with the practice, 
ensuring that each patient was registered with the prac-
tice for at least one year before cancer diagnosis. We 
used the date of cancer diagnosis from the linked can-
cer registry data as the index date for entry to the 
cohort, and patients were followed up until the earliest 
of the date of death or 31 December 2015 to ensure a 
minimum of 12 months’ follow-up after diagnosis.
We excluded patients where the growth behaviour for 
the index cancer diagnosis was coded as benign and 
those where the diagnosis was made on or after death, 
because the duration of survival is unknown.14  15
external validation cohort
For the separate external validation cohort, we identi-
fied patients aged 15 to 99 years with a diagnosis of col-
orectal cancer recorded on the PHE cancer registry who 
were not registered with QResearch practices at the 
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time of diagnosis, excluding those where the growth 
behaviour of their cancer was coded as benign and 
those with a death certificate only diagnosis.
Outcomes
Our primary outcome was all cause mortality. Our sec-
ondary outcome was colorectal cancer mortality. We 
used the primary and underlying causes of death on the 
linked ONS record to identify deaths from colorectal 
cancer.
Predictor variables
Box 1 lists the predictor variables we examined, based 
on established factors affecting mortality after a diag-
nosis of cancer and those affecting all cause mortality. 
We did this so that the absolute risk estimates will be 
able to reflect these factors.
For body mass index, smoking status, and alcohol 
consumption, we used the most recent value before 
cancer diagnosis. For blood tests, we used the values 
recorded closest to the date of diagnosis, selecting 
from those recorded within 12 months either side of 
the diagnosis date. For comorbidities, family history, 
use of statins, and use of aspirin we used values 
recorded before diagnosis. We also included the 
Townsend deprivation score, which is an area level 
score based on the patients’ postcode.23  Originally 
developed by Townsend,23 it includes unemployment 
(as a percentage of those aged 16 or more who are eco-
nomically active), non-car ownership (as a percentage 
of all households), non-home ownership (as a percent-
age of all households), and household overcrowding. 
These variables are measured for a given area of 
approximately 120 households, using the 2011 census, 
and combined to give a Townsend score for that area. 
A greater Townsend score implies a greater level of 
deprivation.
Derivation of the predictive models
We developed the risk models using cause specific haz-
ard models to account for competing risks such as death 
from other causes. Firstly, we used multiple imputation 
with chained equations to replace missing values for 
continuous values (body mass index) and categorical 
variables (smoking status, alcohol consumption, can-
cer stage, and cancer grade).24-26  We carried out five 
imputations and included all potential predictor vari-
ables in each imputation model along with the outcome 
variables, the Nelson-Aalen estimator of the baseline 
cumulative hazard,27 and the interaction terms.
Secondly, we fitted two separate cause specific Cox 
models: one for deaths from colorectal cancer and one 
for deaths from other causes. To allow for clustering of 
patients within general practices, we used robust vari-
ance estimates. We used fractional polynomial terms28 
to model non-linear risk relations for age and body mass 
index. We used Rubin’s rules to combine the regression 
coefficients across the five imputed datasets.29  Variables 
were retained in the prediction models if they had a haz-
ard ratio of <0.85 or >1.15 (for binary variables) and were 
statistically significant at the 0.01 level. We tested for 
two way interactions between age and each predictor; 
cancer stage and each predictor; and combinations of 
cancer grade, surgery, and chemotherapy. We included 
significant interactions (where P<0.01). A formula30 was 
used to derive the cumulative incidence function for col-
orectal cancer mortality accounting for competing risk 
of death from other causes using estimates obtained 
from the two Cox models. This formula multiplies the 
hazard contribution for colorectal cancer mortality at a 
given time by the probability of death from other causes 
at that time and then sums these values across the time 
period of interest. We used the same method to derive 
the cumulative incidence function for deaths from other 
causes, accounting for competing risk of death from col-
orectal cancer. We added these two cumulative inci-
dence functions to give estimates of the risk of death 
from all causes. We obtained values of these estimates at 
1, 5, and 10 years after diagnosis and hence derived esti-
mates of absolute survival probabilities at 1, 5, and 10 
years after diagnosis.
box 1: Predictor variables
variables derived from Public health england cancer registry
Age at diagnosis15
Self assigned ethnicity (white or not recorded, Indian, Pakistani, Bangladeshi, other 
Asian, Caribbean, black African, Chinese, or other)
Townsend deprivation score
Cancer stage15 16  classified using Tumour Nodes Metastases classification (version 7)17 
(stage 1: local involvement only, stage 2: extension to adjacent tissue, stage 3: lymph 
node involvement, stage 4: metastasis, or not recorded)
Cancer grade (well differentiated, moderately differentiated, poorly differentiated, 
and undifferentiated, or not recorded)
Colorectal cancer surgery within a year of diagnosis
Chemotherapy within a year of diagnosis
Radiotherapy within a year of diagnosis
variables derived from patients linked gP record
Most recent smoking status before diagnosis (non-smoker, former smoker, light 
smoker <10/day, moderate smoker 10-19/day, or heavy smoker ≥20/day)
Most recent alcohol status before diagnosis (non-drinker, trivial: <1 unit/day, light: 1-2 
units/day, or moderate or heavy: >3 units/day)
Family history of bowel cancer (yes or no)
Previous cancer (other than colorectal) (yes or no)
Cardiovascular disease (yes or no)
Diabetes (type 1, type 2, or no diabetes)
Chronic renal disease (yes or no)
Chronic liver disease (yes or no)
Inflammatory bowel disease (yes or no)
Chronic obstructive pulmonary disease (yes or no)
Venous thromboembolism (yes or no)
Statin use18 19 (yes or no)
Aspirin use20 21 (yes or no)
Abnormal platelet count defined as values >480×109/L
Abnormal liver function test result, defined as either γ glutamyltransferase or alanine 
aminotransferase or bilirubin more than three times normal22 based on the value 
closest to cancer diagnosis (yes or no)
Anaemia, defined as haemoglobin <110 g/L (yes or no)
Most recent body mass index before diagnosis
Self assigned ethnicity where not recorded on the PHE cancer registry (white or not 
recorded, Indian, Pakistani, Bangladeshi, other Asian, Caribbean, black African, 
Chinese, or other)
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Conditional survival
Overall survival
We calculated overall survival estimates conditional on 
having survived a given number of years after diagnosis 
(X) for patients who had already survived Y years since 
diagnosis by dividing the absolute survival at X years by 
the absolute overall survival estimates at Y years.31
Cause specific mortality
To calculate cause specific mortality estimates at a 
given number of years after diagnosis (X) for patients 
who had already survived Y years since diagnosis, we 
calculated the cumulative risk at X years minus the 
cumulative risk at Y years and divided this difference by 
the overall survival at Y years (ie, ((cumulative risk at X 
years)–(cumulative risk at Y years))/overall survival at 
Y years). In this way it is possible to calculate predic-
tions for overall survival as well as cause specific mor-
tality conditional on survival for any number of years 
for each year until 10 years.
landmark analysis
Patients were recorded on the PHE cancer registry as 
having received chemotherapy or colorectal surgery if 
this was undertaken within a year of the date of diagno-
sis of cancer but the precise date of treatment was 
unavailable. As a further analysis we therefore under-
took a landmark analysis32  to avoid immortal time bias 
(which would tend to overestimate the benefit of treat-
ment)33 and compared hazard ratios for cancer treat-
ments with the main analysis. We assigned a landmark 
date that was 365 days after cancer diagnosis. Deaths 
that occurred between the diagnosis date and landmark 
date were excluded from these analyses.
validation of the predictive models
We used multiple imputation in the QResearch validation 
cohort to replace missing values using the same imputa-
tion model as in the derivation cohort. In the PHE valida-
tion cohort, we used multiple imputation to replace 
missing values for cancer stage and grade only. The risk 
equations were applied to both the QResearch and the PHE 
validation cohort. We assumed zero values for variables in 
the model that were not recorded on the PHE dataset (these 
variables were family history of bowel cancer, raised plate-
let count, abnormally raised liver function test result, statin 
use, aspirin use, cardiovascular disease, diabetes, renal 
disease, and chronic obstructive pulmonary disease). A 
value of 25 kg/m2 was assumed for body mass index.
We calculated R2 values (explained variation in time 
to death34 ), D statistics35  (measure of discrimination, 
where higher values indicate better discrimination), and 
Harrell’s C statistics over 1, 5, and 10 years. Harrell’s C 
statistic36  is a measure of discrimination that is similar 
to the receiver operating characteristic statistic but takes 
account of the censored nature of the data. Using 
Rubin’s rules we combined these model performance 
measures across imputed datasets. We assessed calibra-
tion for all cause mortality by comparing the observed 
risks at 1, 5, and 10 years with the mean predicted risks 
by 10th of predicted risk using Kaplan-Meier estimates 
of observed risk. Calibration of the colorectal mortality 
estimates was assessed by comparing non-parametric 
estimates of cumulative incidence, which approximate 
observed risk accounting for competing risk of death 
from other causes,37 with the mean predicted risks 
across 10ths of predicted risk. A model is well calibrated 
if predicted risks closely approximate the observed risks.
survival rates
In each of the three cohorts we calculated the age stan-
dardised observed survival and the relative net survival 
for patients from the date of diagnosis for comparisons 
with other studies.14 38  Relative survival is the ratio of 
the overall survival for a cohort of patients with cancer 
to the expected survival in the general population 
matched by age, sex, and calendar year. We used back-
ground rates obtained from ONS. We also calculated 
survival estimates for patients, conditional on the 
patient surviving for each year after diagnosis.14 39
Decision curve analysis
We used decision curve analysis in the QResearch vali-
dation cohort (accounting for competing risks) to evalu-
ate the net benefits of the new risk equations for deaths 
from colorectal cancer and from other causes.40-42 This 
approach assesses the benefits of correctly detecting 
people who will have an event compared with the harms 
from a false positive classification (which could lead to 
unnecessary treatment). The net benefit of a risk equa-
tion at a given risk threshold is calculated by calculating 
the difference between the proportion of true positives 
and the proportion of false positives multiplied by the 
odds of the risk threshold. We calculated the net benefits 
across a range of threshold probabilities and compared 
these with alternative strategies such as not treating 
anyone or treating everyone. In general, the strategy 
with the highest net benefit at any given risk threshold is 
considered to have the most clinical value.
To maximise power and generalisability we included 
all the eligible patients in each database. All analyses 
were done using STATA (version 14.1). We adhered to 
the transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis (TRIPOD) 
statement for reporting.43  Further details can be found 
in the study protocol.44
Patient involvement
Patients were not involved in setting the research ques-
tion. A patient representative reviewed the study proto-
col and advised on the design and outcome measures 
and the lay summary. Patient representatives from the 
QResearch advisory board have written the information 
for patients on the QResearch website about the use of 
the database for research in general. They have also 
advised on dissemination, including the use of lay sum-
maries describing the research and its results.
Results
Overall study population
Overall, 1252 practices in England participating in QRe-
search met our practice inclusion criteria, of which 947 
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were randomly assigned to the derivation dataset with 
the remaining 305 practices assigned to the validation 
cohort. Overall we identified 525 416 patients with a 
diagnosis of colorectal cancer on the Public Health 
England (PHE) cancer registry between 1998 and 2014. 
We excluded 475 patients who were aged less than 15 
years or more than 99 years, two patients where the 
behaviour of the tumour was benign, and 18 248 
patients where the diagnosis was made on or after 
death. Of the remaining 497 180 patients, 44 145 were 
registered with QResearch practices in the derivation 
cohort and 15 214 were in the QResearch validation 
cohort, leaving 437 821 patients for inclusion in the PHE 
validation cohort.
baseline characteristics
Table 1  shows the baseline characteristics of men and 
women with colorectal cancer for each cohort using 
data from the cancer registry. Table 2 shows additional 
data available from the general practice record. For the 
44 145 patients in the derivation cohort, the mean age 
at diagnosis was 71.6 years. In total, 28 220 (63.9%) had 
colon cancer, 12 674 (28.7%) had rectal cancer, and 
3251 (7.4%) had rectosigmoid cancer; 32 237 (73.0%) 
had cancer stage recorded and 34 370 (77.9%) had 
grade recorded; 33 268 (75.4%) were treated with col-
orectal surgery and 13 567 (30.7%) had chemotherapy. 
Of the 13 567 patients who had chemotherapy, 327 
(2.4%) had stage 1 cancer, 2235 (16.5%) had stage 2 
cancer, 5717 (42.1%) had stage 3 cancer, and 2277 
(20.4%) had stage 4 cancer, and in 2516 (18.5%) stage 
was not recorded. Smoking status was recorded in 
41 449 (93.9%) of patients, ethnicity in 38 544 (87.3%), 
and body mass index in 36 979 (83.8%). In the deriva-
tion cohort, 17 642 (40.0%) had complete data for all 
the variables compared with 5716 (37.6%) in the valida-
tion cohort. Table 1 in the web appendix shows sum-
mary statistics of predictor variables for patients with 
complete data compared with those with one or more 
missing values.
Baseline characteristics of both men and women 
were similar in the derivation and validation cohorts. 
However, there were some differences in baseline char-
acteristics between the sexes. For example, in the QRe-
search derivation cohort, 69.1% of women had colon 
cancer compared with 59.7% of men. Use of chemother-
apy and radiotherapy was higher in men than in women 
(33.0% v 27.9% and 16.8% v 11.8%, respectively). Men 
were more likely than women to be former smokers 
(table 2, 40.1% v 24.9%), have cardiovascular disease 
(23.3% v 15.5%), and have type 2 diabetes (14.8% v 
11.2%). Men were also more likely to be prescribed 
statins (29.7% v 21.6%) and aspirin (24.5% v 17.0%) at 
diagnosis. Women were more likely than men to be 
anaemic at diagnosis (28.3% v 20.3%) and have raised 
platelet count (11.85 v 6.6%).
Table 2 in the web appendix compares baseline char-
acteristics of men and women with and without a fam-
ily history of bowel cancer. Women with a family history 
tended to be more affluent, have a diagnosis at an ear-
lier stage, and were more likely to have surgery than 
women without a family history. These differences were 
less noticeable in men.
Primary outcomes
In the 44 145 patients in the derivation cohort, there 
were 26 887 deaths during follow-up, and of these, 
13 588 (50.5%) were recorded as due to colorectal can-
cer. Of the 15 214 patients in the QResearch validation 
cohort, there were 9404 deaths, and of these, 4770 
(50.7%) were recorded as due to colorectal cancer. Of 
the 437 821 patients in the PHE validation cohort, 
there were 277 628 deaths. Information on cause of 
death for patients in the PHE validation cohort was 
not available.
Table 3  shows the 5 and 10 year age standardised 
observed and relative net survival values for each 
cohort. Table 3 also shows the observed and relative 
net survival since diagnosis conditional on surviving 
the first year, which shows a noticeable improvement.
Models
Colorectal cancer mortality
Table 4  shows the adjusted hazard ratios for deaths 
from colorectal cancer for variables in the final model 
for men and women in the derivation cohort. Details 
of the fractional polynomial terms for age and body 
mass index and statistically significant interactions 
are shown in the footnote of table 3  and figure 1 . The 
final models included several variables: age, depriva-
tion, cancer stage, cancer grade, smoking status, col-
orectal cancer surgery, chemotherapy, family history 
of bowel cancer, raised platelet count, abnormal liver 
function test result, cardiovascular disease, diabetes, 
and prescribed aspirin and statins at diagnosis. In 
women, increased survival was associated with 
younger age, colorectal cancer surgery (adjusted haz-
ard ratio 0.47, 95% confidence interval 0.44 to 0.51), 
family history of bowel cancer (0.58, 0.46 to 0.74), and 
prescriptions for statins (0.72, 0.66 to 0.78) and aspi-
rin (0.86, 0.77 to 0.96) at diagnosis. The results for 
men were comparable except for family history where 
the adjusted hazard ratio for men was 0.82 (0.67 to 
0.98). Poorer survival in men and women was associ-
ated with a later stage of cancer, a poorly differenti-
ated grade, increasing deprivation, heavy smoking, 
raised platelet count, abnormally raised liver func-
tion test result, diagnosis of cardiovascular disease, 
and type 2 diabetes. There were statistically signifi-
cant interactions in men and women between age and 
cancer stage and between chemotherapy and cancer 
stage (table 4 ) and in women between age and aspirin 
use (fig 1). In women, cancer stage was strongly asso-
ciated with colorectal cancer mortality. For example, 
in those who did not have chemotherapy the risk of 
death from colorectal cancer in those with stage 4 
cancer was 35 times higher (adjusted hazard ratio 
35.6, 26.5 to 47.9) than women with stage 1 cancer. 
These hazard ratios were lower in women who had 
chemotherapy. In men and women with stage 1 and 2 
cancer those receiving chemotherapy had an 
increased risk of colorectal cancer mortality  compared 
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with those not receiving chemotherapy, in patients 
with stage 3 or 4 cancer, chemotherapy was associ-
ated with a reduced risk of colorectal cancer mortal-
ity. For example, in women with stage 1 cancer the 
risk of colorectal mortality was 3.2 times higher in 
those who had chemotherapy than in those who did 
not have chemotherapy (3.21, 1.95 to 5.31). For women 
with stage 4 cancer, chemotherapy was associated 
with a 44% lower risk of death from colorectal cancer 
(0.56, 0.49 to 0.63).
table 1 | baseline characteristics of men and women with colorectal cancer aged 15-99 years in the Qresearch derivation cohort and Qresearch and 
Public health england (Phe) validation cohorts based on information recorded in the cancer registry. values are numbers (percentages) unless stated 
otherwise
Characteristics
Women Men
Qresearch 
derivation cohort
Qresearch 
validation cohort
Phe validation 
cohort
Qresearch 
derivation cohort
Qresearch 
validation cohort
Phe validation 
cohort
Total No of patients 19 708 6800 196 239 24 437 8414 241 582
Mean (SD) age at diagnosis (years) 72.5 (12.8) 72.7 (12.8) 72.5 (12.9) 70.9 (11.5) 70.9 (11.6) 70.5 (11.7)
Age group (years):
 15-19 17 (0.1) 4 (0.1) 181 (0.1) 6 (0.0) 3 (0.0) 119 (0.0)
 20-29 67 (0.3) 33 (0.5) 817 (0.4) 65 (0.3) 16 (0.2) 775 (0.3)
 30-39 241 (1.2) 68 (1.0) 2201 (1.1) 215 (0.9) 93 (1.1) 2420 (1.0)
 40-49 729 (3.7) 251 (3.7) 7279 (3.7) 807 (3.3) 266 (3.2) 8113 (3.4)
 50-59 1960 (9.9) 650 (9.6) 20 146 (10.3) 2679 (11.0) 931 (11.1) 27 545 (11.4)
 60-69 4097 (20.8) 1408 (20.7) 40 588 (20.7) 6376 (26.1) 2197 (26.1) 64 424 (26.7)
 70-79 6069 (30.8) 2084 (30.6) 59 928 (30.5) 8356 (34.2) 2854 (33.9) 82 423 (34.1)
 80-89 5371 (27.3) 1896 (27.9) 53 492 (27.3) 5257 (21.5) 1817 (21.6) 49 535 (20.5)
 90-99 1157 (5.9) 406 (6.0) 11 607 (5.9) 676 (2.8) 237 (2.8) 6228 (2.6)
Ethnicity:
 Recorded 17005 (86.3) 5896 (86.7) 144409 (73.6) 21539 (88.1) 7435 (88.4) 184127 (76.2)
 White or not recorded 19150 (97.2) 6603 (97.1) 191 802 (97.7) 23 699 (97.0) 8183 (97.3) 235 692 (97.6)
 Indian 84 (0.4) 28 (0.4) 756 (0.4) 147 (0.6) 40 (0.5) 1184 (0.5)
 Pakistani 32 (0.2) 14 (0.2) 373 (0.2) 57 (0.2) 10 (0.1) 495 (0.2)
 Bangladeshi 40 (0.2) 12 (0.2) 139 (0.1) 48 (0.2) 14 (0.2) 166 (0.1)
 Other Asian 53 (0.3) 14 (0.2) 297 (0.2) 60 (0.2) 18 (0.2) 404 (0.2)
 Black Caribbean 123 (0.6) 54 (0.8) 900 (0.5) 168 (0.7) 61 (0.7) 1097 (0.5)
 Black African 49 (0.2) 18 (0.3) 386 (0.2) 67 (0.3) 22 (0.3) 429 (0.2)
 Chinese 27 (0.1) 13 (0.2) 302 (0.2) 34 (0.1) 17 (0.2) 377 (0.2)
 Other 150 (0.8) 44 (0.6) 1284 (0.7) 157 (0.6) 49 (0.6) 1738 (0.7)
Year of diagnosis:
 1998-2005 7462 (37.9) 2625 (38.6) 87 301 (44.5) 8786 (36.0) 3174 (37.7) 104 651 (43.3)
 2006-14 12 246 (62.1) 4175 (61.4) 108 938 (55.5) 15 651 (64.0) 5240 (62.3) 136 931 (56.7)
Type of cancer:
 Colon 13 641 (69.2) 4580 (67.4) 134  832 (68.7) 14 579 (59.7) 5078 (60.4) 143 254 (59.3)
 Rectal 4735 (24.0) 1710 (25.1) 47 966 (24.4) 7939 (32.5) 2694 (32.0) 78 821 (32.6)
 Rectosigmoid 1332 (6.8) 510 (7.5) 13 441 (6.8) 1919 (7.9) 642 (7.6) 19 507 (8.1)
Townsend deprivation fifth:
 1 (most affluent) 4505 (22.9) 1594 (23.4) 37 911 (19.3) 5649 (23.1) 2076 (24.7) 48 605 (20.1)
 2 4612 (23.4) 1460 (21.5) 42 934 (21.9) 5775 (23.6) 1788 (21.3) 52 517 (21.7)
 3 3968 (20.1) 1419 (20.9) 43 032 (21.9) 4837 (19.8) 1636 (19.4) 51 619 (21.4)
 4 3559 (18.1) 1275 (18.8) 39 510 (20.1) 4236 (17.3) 1484 (17.6) 47 309 (19.6)
 5 (most deprived) 3064 (15.5) 1052 (15.5) 32 852 (16.7) 3940 (16.1) 1430 (17.0) 41 532 (17.2)
Cancer stage at diagnosis:
 Stage recorded 14 193 (72.0) 4724 (69.5) 140 613 (71.7) 18 044 (73.8) 5918 (70.3) 177 401 (73.4)
 1 2030 (10.3) 697 (10.3) 19 542 (10.0) 2763 (11.3) 938 (11.1) 26 977 (11.2)
 2 4926 (25.0) 1592 (23.4) 47 791 (24.4) 5783 (23.7) 1942 (23.1) 57 679 (23.9)
 3 4715 (23.9) 1645 (24.2) 48 194 (24.6) 6205 (25.4) 2052 (24.4) 60 040 (24.9)
 4 2522 (12.8) 790 (11.6) 25 086 (12.8) 3293 (13.5) 986 (11.7) 32 705 (13.5)
Cancer grade at diagnosis:
 Grade recorded 15 077 (76.5) 5066 (74.5) 147 796 (75.3) 19 293 (78.9) 6508 (77.3) 189 146 (78.3)
 Well differentiated 1110 (5.6) 366 (5.4) 10 499 (5.4) 1306 (5.3) 479 (5.7) 13 168 (5.5)
 Moderately differentiated 11 162 (56.6) 3787 (55.7) 109 278 (55.7) 15 003 (61.4) 5122 (60.9) 147 237 (60.9)
 Poorly differentiated 2777 (14.1) 900 (13.2) 27 589 (14.1) 2949 (12.1) 893 (10.6) 28 332 (11.7)
 Undifferentiated 28 (0.1) 13 (0.2) 430 (0.2) 35 (0.1) 14 (0.2) 409 (0.2)
Treatment within 12 months of diagnosis:
 Surgery 14 729 (74.7) 4971 (73.1) 145 376 (74.1) 18 539 (75.9) 6276 (74.6) 182 573 (75.6)
 Chemotherapy 5504 (27.9) 1849 (27.2) 52 228 (26.6) 8063 (33.0) 2665 (31.7) 76 495 (31.7)
 Radiotherapy 2325 (11.8) 870 (12.8) 22 255 (11.3) 4116 (16.8) 1361 (16.2) 39 175 (16.2)
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Other cause mortality
Table 5  shows the adjusted hazard ratios for mortality 
from other causes. The hazard ratios for fractional 
 polynomial terms are shown in figure 1. The model 
included all the predictors in the colorectal cancer 
mortality model as well as chronic obstructive pulmo-
nary disease and chronic renal disease. The direction 
of the hazard ratios was similar to that for the colorec-
tal mortality model, although the magnitude of the 
hazard ratios was less for cancer grade and stage. In 
women there was an interaction between age and 
aspirin use. In men and women there were interac-
tions between age and cancer stage, chemotherapy 
and cancer stage, cardiovascular disease and cancer 
stage, and chronic obstructive pulmonary disease and 
cancer stage. For example, in women with stage 1 can-
cer, those with cardiovascular disease had a 39% 
increased risk of other cause mortality compared with 
those without cardiovascular disease (adjusted hazard 
ratio 1.39, 95% confidence interval 1.07 to 1.80). Simi-
larly, in women with stage 1 cancer, those with chronic 
obstructive pulmonary disease had a 111% increased 
risk of other cause mortality compared with those 
without chronic obstructive pulmonary disease (2.11, 
1.54 to 2.89). The interactions between chemotherapy 
and cancer stage showed a reduced risk for chemo-
therapy in people with stage 3 and stage 4 disease. For 
example, in women with stage 4 cancer those who had 
chemotherapy had a 49% lower risk of other cause 
mortality compared with those did not have chemo-
therapy (0.51, 0.44 to 0.60).
Landmark analysis
We undertook a landmark analysis, restricted to the 
13 926 women and 17 935 men who survived the first year 
after diagnosis. The results for colorectal mortality are 
shown in table 3 in the web appendix. The adjusted haz-
ard ratio for colorectal surgery in women was 0.65 (95% 
confidence interval 0.59 to 0.71) and for chemotherapy 
(stage 1 cancer) was 1.97 (1.40 to 2.75). The correspond-
ing figures in men were 0.62 (0.56 to 0.67) and 1.71 (1.34 
to 2.16). In men and women with stage 3 and 4 cancer, 
chemotherapy was not associated with a reduced risk of 
death from colorectal cancer.
validation—discrimination and calibration
Table 6 shows the performance of each equation in 
both validation cohorts for five year survival esti-
mates. Table 4 in the web appendix shows the corre-
sponding results at 1 and 10 years. For example, in 
women the five year equation for colorectal cancer 
mortality explained 45.3% of the variation in the QRe-
search validation cohort; the D statistic was 1.86 and 
Harrell’s C statistic was 0.80. The corresponding 
results for all cause mortality were 42.6%; 1.77 and 
0.79. Performance for one year risk estimates was mar-
ginally better and those for 10 year estimates were 
marginally worse (see table 4 in the web appendix). 
Overall, performance in the QResearch validation 
cohort was marginally better than that in the PHE 
cohort for all comparisons in both men and women 
and at all time points.
Figure 2 shows the mean predicted risks and observed 
risks by 10th of predicted risk at 1, 5, and 10 years for 
men and women for all cause mortality in both valida-
tion cohorts as well as the corresponding graphs for 
colorectal cancer mortality in the QResearch validation 
cohort. The correspondence was close between the 
mean predicted risks and the observed risks, indicating 
that the equations were well calibrated for each of the 
time points and across both validation cohorts and for 
both outcomes.
Decision curve analysis
Figure 3 displays the net benefit curves for both colorec-
tal cancer mortality and other cause mortality  equations 
table 2 | baseline characteristics of patients with colorectal cancer aged 15-99 years in 
Qresearch derivation and validation cohorts using information derived from the linked 
primary care data. values are numbers (percentages)
Characteristics
Women Men
Derivation 
cohort
validation 
cohort
Derivation 
cohort
validation 
cohort
Total No of patients 19 708 6800 24 437 8414
Smoking status:
 Recorded 18 405 (93.4) 6320 (92.9) 23 044 (94.3) 7936 (94.3)
 Non-smoker 11 416 (57.9) 3901 (57.4) 10 115 (41.4) 3473 (41.3)
 Former smoker 4898 (24.9) 1691 (24.9) 9806 (40.1) 3347 (39.8)
 Light smoker 1195 (6.1) 433 (6.4) 1994 (8.2) 693 (8.2)
 Moderate smoker 584 (3.0) 191 (2.8) 620 (2.5) 214 (2.5)
 Heavy smoker 312 (1.6) 104 (1.5) 509 (2.1) 209 (2.5)
Alcohol consumption:
 Recorded 16 398 (83.2) 5590 (82.2) 20 776 (85.0) 7102 (84.4)
 Non-drinker 7460 (37.9) 2466 (36.3) 5160 (21.1) 1779 (21.1)
 Trivial, <1 unit/day 5701 (28.9) 2015 (29.6) 6025 (24.7) 2079 (24.7)
 Light, 1-2 units/day 1873 (9.5) 645 (9.5) 3584 (14.7) 1225 (14.6)
 Moderate or heavy, >3 units/day 1355 (6.9) 462 (6.8) 5965 (24.4) 2010 (23.9)
Medical history:
 Family history of bowel cancer 514 (2.6) 186 (2.7) 481 (2.0) 159 (1.9)
 Other cancer 1570 (8.0) 553 (8.1) 1912 (7.8) 632 (7.5)
 CVD 3054 (15.5) 1067 (15.7) 5701 (23.3) 1984 (23.6)
 Type 1 diabetes 29 (0.1) 15 (0.2) 68 (0.3) 25 (0.3)
 Type 2 diabetes 2207 (11.2) 766 (11.3) 3617 (14.8) 1236 (14.7)
 Chronic renal disease 266 (1.3) 80 (1.2) 343 (1.4) 122 (1.4)
 Chronic liver disease 143 (0.7) 55 (0.8) 242 (1.0) 79 (0.9)
 Inflammatory bowel disease 301 (1.5) 96 (1.4) 366 (1.5) 122 (1.4)
 COPD 1035 (5.3) 391 (5.8) 1930 (7.9) 680 (8.1)
 VTE 901 (4.6) 295 (4.3) 939 (3.8) 357 (4.2)
 Prescribed statins at diagnosis 4258 (21.6) 1412 (20.8) 7246 (29.7) 2440 (29.0)
 Prescribed aspirin at diagnosis 3349 (17.0) 1179 (17.3) 5986 (24.5) 2123 (25.2)
Haemoglobin level recorded 15 339 (77.8) 5288 (77.8) 18 490 (75.7) 6269 (74.5)
Platelet count recorded 15 280 (77.5) 5257 (77.3) 18 403 (75.3) 6233 (74.1)
Liver function test result recorded 14 146 (71.8) 4869 (71.6) 17 853 (73.1) 6037 (71.7)
Haemoglobin <110 g/L 5581 (28.3) 1906 (28.0) 4954 (20.3) 1716 (20.4)
Raised platelet count 2321 (11.8) 791 (11.6) 1607 (6.6) 561 (6.7)
Abnormally raised liver function test result 697 (3.5) 229 (3.4) 1188 (4.9) 401 (4.8)
Body mass index (kg/m2):
 Recorded 16 368 (83.1) 5620 (82.6) 20 611 (84.3) 7032 (83.6)
 <20 1029 (5.2) 342 (5.0) 509 (2.1) 214 (2.5)
 20-24.9 5859 (29.7) 2015 (29.6) 6158 (25.2) 2149 (25.5)
 25-29.9 5674 (28.8) 1912 (28.1) 9268 (37.9) 3092 (36.7)
 30-34.9 2665 (13.5) 924 (13.6) 3636 (14.9) 1236 (14.7)
 ≥35 1141 (5.8) 427 (6.3) 1040 (4.3) 341 (4.1)
CVD=cardiovascular disease; COPD=chronic obstructive pulmonary disease; VTE=venous thromboembolism.
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at five years in men and women. The prediction equa-
tions for colorectal mortality and for other cause mor-
tality had higher net benefit than strategies based on 
considering either no patients or all patients for inter-
vention across a range of risk thresholds.
Web calculator
Figures 4 and 5 show a clinical example of the imple-
mentation of the equations as a web calculator (http://
qcancer.org/colorectal-survival/index.php), illustrating 
how the number of years since diagnosis affects sur-
vival estimates. The example in figure 4  is for a 38 year 
old woman with grade 1, stage 4 colorectal cancer who 
has had a hemicolectomy and chemotherapy. Her initial 
five year survival estimate at diagnosis is 45.0% (white 
bar), risk of death from colorectal cancer is 35.6% (blue 
bar), and risk of death from other causes is 19.4% (dark 
blue bar). Having survived for 12 months since diagno-
sis, her five year survival estimate is 57.1%, her five year 
risk of death from colorectal cancer is 25.8%, and her 
five year risk of death from other causes is 17.0% (fig 5).
Figures 6 and 7  show a second example, illustrating 
how the general practice derived variables affect sur-
vival estimates. The example in figure 6  is for a 65 year 
old woman with grade 3, stage 2, colorectal cancer who 
is a non-smoker. Her five year survival estimate at diag-
nosis is 63.1% (white bar), five year risk of death from 
colorectal cancer is 21.6% (blue bar), and risk of death 
from other causes is 15.3% (dark blue bar). If she is a 
heavy smoker, has stage 4 or 5 kidney disease, an abnor-
mal liver function test result, and raised platelet count, 
her five year survival estimate is 24.9%, her five year risk 
of death from colorectal cancer is 39.5%, and her five 
year risk of death from other causes is 35.6% (fig 7).
Figure 8  shows a third example, illustrating how the 
competing risk of death from other causes (dark blue 
bar) becomes the predominant factor over time, espe-
cially in elderly people. The example in figure 8 is for an 
table 3 | age standardised observed and relative net survival rates for patients with colorectal cancer aged 15-99 years 
in the Qresearch derivation cohort and both validation cohorts. values are percentages unless stated otherwise
variables
Qresearch derivation cohort Qresearch validation cohort Phe validation cohort
Observed 
(%)
relative net 
survival (95% Ci)*
Observed 
(%)
relative net 
survival (95% Ci)
Observed 
(%)
relative net 
survival (95% Ci)
since diagnosis
5 years:
 Overall 43.5 52.3 (51.7 to 52.9) 42.8 51.5 (50.4 to 52.5) 42.5 51.2 (51.0 to 51.4)
 Stage 1 75.0 92.2 (89.8 to 94.1) 76.4 93.4 (88.5 to 96.2) 74.4 91.7 (90.9 to 92.4)
 Stage 2 66.1 81.5 (80.1 to 82.8) 64.0 78.6 (76.2 to 80.8) 64.0 79.4 (78.9 to 79.8)
 Stage 3 43.7 52.9 (51.5 to 54.2) 42.9 52.3 (49.9 to 54.7) 43.1 52.1 (51.7 to 52.6)
 Stage 4 7.9 9.2 (8.3 to 10.1) 8.5 9.8 (8.3 to 11.5) 7.7 8.8 (8.6 to 9.1)
 Not recorded 31.2 36.4 (35.4 to 37.4) 30.5 35.7 (34.0 to 37.3) 30.4 35.5 (35.1 to 35.8)
10 years:
 Overall 31.9 49.4 (48.1 to 50.6) 31.8 48.1 (46.3 to 49.9) 30.8 47.3 (47.0 to 47.7)
 Stage 1 56.9 91.6 (82.2 to 96.1) 56.2 † 55.6 90.2 (87.3 to 92.5)
 Stage 2 48.5 80.2 (75.8 to 83.9) 47.1 76.6 (69.8 to 82.1) 45.9 76.3 (75.1 to 77.6)
 Stage 3 30.3 49.0 (45.3 to 52.6) 30.9 47.7 (42.8 to 52.5) 30.0 47.2 (46.2 to 48.3)
 Stage 4 4.7 12.1 (7.5 to 17.9) NS NS 4.7 6.7 (6.1 to 7.3)
 Not recorded 23.5 33.0 (31.5 to 34.6) 23.7 32.3 (30.3 to 34.3) 22.6 31.6 (31.2 to 32.0)
1 year conditional survival
5 years:
 Overall 60.2 71.3 (70.6 to 72.1) 59.9 70.9 (69.5 to 72.2) 59.8 71.1 (70.9 to 71.4)
 Stage 1 80.9 96.2 (93.4 to 97.8) 82.6 98.4 (80.4 to 99.9) 80.4 95.7 (94.9 to 96.3)
 Stage 2 74.1 88.5 (87.1 to 89.8) 72.3 86.3 (83.7 to 88.6) 72.5 87.2 (86.8 to 87.7)
 Stage 3 54.4 64.6 (62.9 to 66.3) 53.9 64.1 (61.2 to 66.9) 54.1 64.2 (63.6 to 64.7)
 Stage 4 19.9 23.9 (21.2 to 26.6) 21.9 25.6 (20.8 to 30.7) 19.8 23.0 (22.2 to 23.8)
 Not recorded 51.3 59.4 (57.9 to 60.9) 50.9 59.3 (56.8 to 61.7) 51.3 59.8 (59.3 to 60.3)
10 years:
 Overall 42.8 65.9 (63.9 to 67.8) 42.9 64.5 (61.4 to 67.4) 41.8 64.2 (63.6 to 64.8)
 Stage 1 60.4 92.3 (83.0 to 96.6) 60.3 † 59.2 90.8 (88.1 to 92.9)
 Stage 2 53.4 84.2 (79.4 to 87.9) 52.1 81.5 (73.5 to 87.3) 50.9 81.0 (79.6 to 82.2)
 Stage 3 37.0 58.4 (53.5 to 63.1) 37.8 56.5 (50.3 to 62.2) 36.7 56.6 (55.2 to 58.0)
 Stage 4 11.4 48.1 (22.0 to 70.3) NS NS 11.5 18.6 (15.4 to 22.1)
 Not recorded 37.1 52.8 (50.0 to 55.5) 37.5 51.5 (48.2 to 54.7) 36.4 51.8 (51.0 to 52.6)
NS=Not sufficient. Too few events occurred in the QResearch validation cohort to calculate 95% confidence intervals or 10 year survival for stage 4 
cancer.
*Relative survival is the ratio of the overall survival for a cohort of patients with cancer to the expected survival in the general population matched by 
age, sex, and calendar year. Background rates were obtained from the Office for National Statistics. Rates were directly age standardised using standard 
weights proposed by Corazziari et al45: 15-44 (7%), 45-54 (12%), 55-64 (23%), 65-74 (29%), >75% (29%).
†Sample too small to calculate 95% confidence interval.
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80 year old woman with stage 1, grade 1 colorectal can-
cer who is a light smoker and has angina. Her estimated 
overall survival at one year (white bar) is 75.1%, at five 
years is 32.2%, and at 10 years is 10.8%. Her risk of 
death from colorectal cancer (blue bar) at  corresponding 
time points is 6.2%, 13.5%, and 14.3%. Her mortality 
from other causes (dark blue bar) at these time points is 
18.4%, 53.9%, and 74.5%. The web calculator can then 
be used to show the risks if she has colorectal surgery 
and/or chemotherapy to help inform her decisions 
about treatments.
discussion
We have developed and externally validated equations 
to predict the absolute risks of both all cause mortality 
and colorectal cancer specific mortality for men and 
women with colorectal cancer over 1, 5, and 10 years. 
The equations are well calibrated and have good dis-
crimination, with Harrell’s C statistics at least 0.76 in 
both validation cohorts for both outcomes (all cause 
mortality and colorectal cancer mortality). These mod-
els are designed to provide better information on sur-
vival for individual patients, taking account of their 
profile, including both conventional factors (age and 
cancer stage) and deprivation index, smoking status, 
common comorbidities, prescribed drugs, and cancer 
treatments such as surgery and chemotherapy. These 
models, based on information likely to be available at 
the point of diagnosis, have been designed to help 
improve the management decisions by patients and cli-
nicians in primary and secondary care.
We have provided a web based calculator (http://
qcancer.org/colorectal-survival/index.php) to illustrate 
how the risks vary with the different predictors and over 
different time periods. The equations to predict abso-
lute risk of death from colorectal cancer account for 
competing risk of death from other causes. This is use-
ful for identifying patients with a high risk of death 
from colorectal cancer but with an otherwise low risk of 
death from other causes for whom more aggressive 
treatment may be appropriate. Equally they can identify 
patients with a low risk of death from colorectal cancer 
and a high risk of death from other causes for whom 
palliative care may be more appropriate. However, man-
agement plans would need to be based on joint deci-
sions between clinicians and patients, reflecting 
individual thoughts around risks and benefits of treat-
ment or concerns about side effects, living circum-
stance, or support available, rather than prespecified 
cut-offs.
We have also provided conditional survival estimates, 
which incorporate how risks change over time. These 
are particularly important among patients where the ini-
tial prognosis is poor owing to late stage disease. For 
example, a 38 year old woman who has just received a 
diagnosis of stage 4 well differentiated colorectal cancer 
may want to know her estimated survival with and with-
out a hemicolectomy and chemotherapy to help her 
assess the potential value of surgery. Using the web cal-
culator, her five year survival estimate would be 5.9% 
without either colorectal surgery or chemotherapy. With 
colorectal surgery alone it would be 22.6% and with both 
treatments it would be 44.8%. This compares with the 
published five year survival estimate of 66% based 
solely on her age (which is an overestimate) or the 8% 
based solely on her cancer stage (which is an underesti-
mate if she receives treatment).2  Assuming she has both 
colorectal surgery and chemotherapy and survives for a 
year after diagnosis, her five year conditional survival 
after diagnosis would have increased to 57.1%. Instead of 
the currently available static prediction based on one or 
two variables, she would be able to obtain dynamic pre-
dictions, which can be updated for each successive year 
after her original diagnosis.31  More accurate dynamic 
survival estimates are particularly valuable for patients 
who need to make important life decisions and whose 
quality of life may be affected by uncertainty about the 
table 4 | adjusted hazard ratios with 95% confidence intervals for death from colorectal 
cancer in men and women in the derivation cohort for the main model 
Predictor variables
adjusted hazard ratio (95% Ci)
Women Men
Townsend score* 1.07 (1.02 to 1.12) 1.05 (1.00 to 1.10)
Smoking status:
 Non-smoker 1.00 1.00
 Former smoker 0.93 (0.86 to 1.00) 0.99 (0.93 to 1.05)
 Light smoker 1.19 (1.03 to 1.39) 1.33 (1.21 to 1.45)
 Moderate smoker 1.16 (0.97 to 1.39) 1.13 (0.97 to 1.32)
 Heavy smoker 1.54 (1.28 to 1.87) 1.48 (1.26 to 1.73)
Cancer stage at diagnosis†:
 1 1.00 1.00
 2 2.79 (2.13 to 3.65) 2.11 (1.66 to 2.67)
 3 10.33 (7.75 to 13.77) 7.48 (6.07 to 9.21)
 4 35.63 (26.52 to 47.85) 30.98 (24.87 to 38.59)
Cancer grade at diagnosis:
 1, well differentiated 1.00 1.00
 2, moderately differentiated 1.12 (0.94 to 1.33) 1.11 (0.98 to 1.26)
 3, poorly differentiated 1.59 (1.33 to 1.90) 1.93 (1.68 to 2.20)
 4, undifferentiated 1.65 (0.90 to 3.02) 2.50 (1.26 to 4.95)
Medical history‡:
 Family history of bowel cancer 0.58 (0.46 to 0.74) 0.81 (0.67 to 0.98)
 Raised platelet count 1.25 (1.15 to 1.37) 1.28 (1.18 to 1.39)
 Abnormal liver function test result 1.35 (1.19 to 1.53) 1.72 (1.56 to 1.89)
 Statin use at diagnosis 0.72 (0.66 to 0.78) 0.67 (0.62 to 0.72)
 Aspirin use at diagnosis 0.86 (0.77 to 0.96) 0.77 (0.72 to 0.82)
 CVD 1.28 (1.16 to 1.41) 1.30 (1.21 to 1.41)
 Type 1 diabetes 0.71 (0.35 to 1.44) 1.32 (0.68 to 2.54)
 Type 2 diabetes 1.12 (1.02 to 1.23) 1.14 (1.05 to 1.24)
Cancer treatments‡:
 Surgery 0.47 (0.44 to 0.51) 0.54 (0.50 to 0.59)
 Chemotherapy (stage 1) 3.21 (1.95 to 5.31) 2.48 (1.64 to 3.74)
 Chemotherapy (stage 2) 1.70 (1.39 to 2.07) 1.60 (1.35 to 1.90)
 Chemotherapy (stage 3) 0.74 (0.66 to 0.84) 0.77 (0.70 to 0.85)
 Chemotherapy (stage 4) 0.56 (0.49 to 0.63) 0.52 (0.48 to 0.57)
CVD=cardiovascular disease.
*Scores range between −7 (most affluent) and 11 (most deprived). Adjusted hazard ratio is per 5 unit increase.
†In people without chemotherapy at the mean age.
‡Adjusted hazard ratio compared with patients without this characteristic. The model for women includes terms 
for age (two fractional polynomial terms, age3 and age3ln(age)) and body mass index (two fractional polynomial 
terms, bmi−2 and ln(bmi)). The model for men includes terms for age (two fractional polynomial terms, age3 and 
age3ln(age)) and body mass index (two fractional polynomial terms, bmi0.5 and bmi). In men and women there 
were interactions between age and cancer stage and between chemotherapy and cancer stage, and in women 
there was an interaction between age and aspirin use.
doi: 10.1136/bmj.j2497 | BMJ 2017;357:j2497 | the bmj
RESEARCH
10
future. For treating doctors, dynamic conditional sur-
vival could help with planning the optimum duration 
and intensity of follow-up.10  Conditional survival esti-
mates could also be used to stratify patients on entry to 
clinical trials. The time at which the conditional survival 
plateaus has been advocated as a potentially important 
endpoint in clinical trial design (eg, the survival for head 
and neck cancer plateaus at three years, leading to sug-
gestions that three year clinical trial data may provide a 
valid endpoint).46
Comparisons with the literature
Our study builds on several original studies that 
have developed colorectal cancer prognostic models 
Colorectal cancer deaths: hazard ratios by age and cancer
stage in women
Colorectal cancer deaths: hazard ratios by age and cancer
stage in men
Age
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
20
30
40
50
60
10
10 20 30 40 50 60 70 80 90 100
Age
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
20
30
40
50
10
10 20 30 40 50 60 70 80 90 100
Stage 1
Stage 2
Stage 3
Stage 4
Stage 1
Stage 2
Stage 3
Stage 4
Colorectal cancer deaths: hazard ratios by body mass
index
Body mass index
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
1.0
1.5
2.0
0.5
15 25 35 45
Hazard ratios compared with BMI = 25Women
Men
Women
Men
Colorectal cancer deaths: hazard ratios for aspirin use by
age in women
Age
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
2
3
4
1
10 20 30 40 50 60 70 80 90 100
Other deaths: hazard ratios by age and cancer stage in
women
Other deaths: hazard ratios by age and cancer stage in
men
Age
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
20
30
40
50
60
10
10 20 30 40 50 60 70 80 90 100
Age
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
20
30
40
50
10
10 20 30 40 50 60 70 80 90 100
Stage 1
Stage 2
Stage 3
Stage 4
Stage 1
Stage 2
Stage 3
Stage 4
Other deaths: hazard ratios for aspirin use by age in
women Other deaths: hazard ratios by body mass index
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
Hazard ratios compared with stage 1 at age 55 Hazard ratios compared with stage 1 at age 55
Hazard ratios compared with stage 1 at age 55 Hazard ratios compared with stage 1 at age 55
Age
0
2
3
1
10 20 30 40 50 60 70 80 90 100
Body mass index
Ad
ju
st
ed
 h
az
ar
d 
ra
tio
0
1.0
1.5
2.0
0.5
15 25 35 45
Hazard ratios compared with BMI = 25
Fig 1 | adjusted hazard ratios for colorectal cancer deaths and other deaths
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to  predict overall survival based on patients 
recruited to clinical trials in USA5  or US cancer regis-
tries.4 6  In contrast with other studies, our model 
predicts both overall survival and colorectal cancer 
specific survival. It also predicts survival over a lon-
ger period (10 years rather than five years). Our 
model provides conditional survival predictions that 
can be updated for each additional year of survival 
since the original cancer diagnosis. It does not, how-
ever, predict recurrence-free survival unlike other 
models,4 5 as the date of recurrence is not well 
recorded on our dataset.
Our model takes account of more variables than 
other models.4-6  The model by Renfo et al5  includes 
age, sex, race, body mass index, performance status, 
cancer grade, cancer stage, ratio of positive lymph 
nodes to nodes examined, number and location of 
primary cancers, and chemotherapy. It can only be 
applied to those with stage 3 cancer. The model by 
Weiser et al includes cancer stage, cancer grade, num-
ber of lymph nodes examined, number of positive 
lymph nodes, age, and sex.6  It can be applied to 
patients who have curative intent surgery. A third 
model, Adjuvant online4  includes cancer stage, can-
cer grade, 10 year age band, sex, and comorbidity 
(perfect health, minor problems, average for age, or 
major problems). It can be applied to patients with 
stage 2 or 3 colon cancer. It has been validated 
although the results focused on calibration rather 
than on discrimination.3 The Adjuvant online model 
itself has not been published and the website is cur-
rently unavailable.
Our models have been developed using a large, rep-
resentative population based cohort and can be 
applied to all patients with a first diagnosis of colorec-
tal cancer including all stages of disease and those 
who have or have not had chemotherapy. Our model 
has better discrimination than previous models, with 
Harrell’s C statistic of 0.76 to 0.78 compared with 0.665 
to 0.68.6  As with the Weiser’s model, our model was 
well calibrated, whereas the Adjuvant online model 
tended to overestimate survival for patients with 
stage 2 disease.3
We included established predictors in our equations 
and report hazard ratios similar in both magnitude and 
direction to those reported elsewhere, increasing the 
clinical validity. For example, the 17-18% reduced all 
table 6 | Performance of the equations in men and women for all cause mortality and colorectal cancer mortality in 
Qresearch validation cohort and Public health england (Phe) cancer registry validation cohort at five year survival
Outcome and 
statistic
Women Men
Qresearch cohort Phe cohort Qresearch cohort Phe cohort
All cause mortality:
 D 1.765 (1.681 to 1.849) 1.656 (1.637 to 1.676) 1.711 (1.651 to 1.771) 1.603 (1.586 to 1.620)
 R2 (%) 42.643 (40.322 to 44.965) 39.579 (39.030 to 40.129) 41.144 (39.447 to 42.841) 38.024 (37.523 to 38.525)
 Harrell’s C 0.787 (0.779 to 0.795) 0.775 (0.773 to 0.776) 0.780 (0.773 to 0.788) 0.763 (0.762 to 0.764)
Colorectal mortality:
 D 1.862 (1.758 to 1.966) NA 1.869 (1.765 to 1.972) NA
 R2 (%) 45.273 (42.507 to 48.038) NA 45.455 (42.729 to 48.182) NA
 Harrell’s C 0.797 (0.784 to 0.810) NA 0.800 (0.791 to 0.809) NA
NA=not available.
table 5 | adjusted hazard ratios with 95% confidence intervals for deaths from other 
causes in men and women in the derivation cohort for the main model. see footnotes for 
fractional polynomial terms
Predictor variables
adjusted hazard ratio (95% Ci)
Women Men
Townsend score* 1.14 (1.08 to 1.19) 1.16 (1.11 to 1.20)
Smoking status:
 Non-smoker 1.00 1.00
 Former smoker 0.99 (0.92 to 1.06) 1.02 (0.97 to 1.08)
 Light smoker 1.57 (1.39 to 1.77) 1.35 (1.23 to 1.49)
 Moderate smoker 1.52 (1.31 to 1.76) 1.73 (1.46 to 2.05)
 Heavy smoker 1.52 (1.18 to 1.97) 1.63 (1.38 to 1.93)
Cancer stage at diagnosis†:
 1 1.00 1.00
 2 1.24 (1.06 to 1.46) 1.21 (1.08 to 1.37)
 3 2.14 (1.78 to 2.57) 2.08 (1.82 to 2.39)
 4 8.53 (7.11 to 10.24) 6.76 (5.72 to 7.98)
Cancer grade at diagnosis:
 1, well differentiated 1.00 1.00
 2, moderately differentiated 0.96 (0.84 to 1.10) 1.03 (0.93 to 1.15)
 3, poorly differentiated 1.27 (1.07 to 1.51) 1.23 (1.08 to 1.39)
 4, undifferentiated 0.84 (0.39 to 1.81) 2.07 (0.89 to 4.83)
Medical history‡:
 Family history of bowel cancer 0.66 (0.54 to 0.80) 0.84 (0.69 to 1.03)
 Raised platelet count 1.04 (0.95 to 1.13) 1.15 (1.05 to 1.27)
 Abnormally raised liver function test result 1.36 (1.16 to 1.59) 1.37 (1.22 to 1.54)
 Statins use at diagnosis 0.84 (0.78 to 0.91) 0.82 (0.78 to 0.87)
 Aspirin use at diagnosis 0.90 (0.81 to 1.00) 0.82 (0.78 to 0.88)
 CVD (stage 1) 1.39 (1.07 to 1.80) 1.67 (1.42 to 1.96)
 CVD (stage 2) 1.01 (0.74 to 1.38) 0.86 (0.70 to 1.04)
 CVD (stage 3) 1.05 (0.76 to 1.44) 0.77 (0.64 to 0.94)
 CVD (stage 4) 0.82 (0.59 to 1.14) 0.74 (0.60 to 0.90)
 Type 1 diabetes 1.60 (0.92 to 2.79) 1.65 (0.90 to 3.03)
 Type 2 diabetes 1.23 (1.12 to 1.34) 1.24 (1.16 to 1.33)
 Renal disease 1.65 (1.39 to 1.96) 1.55 (1.29 to 1.86)
 COPD (stage 1) 2.11 (1.54 to 2.89) 1.63 (1.33 to 2.00)
 COPD (stage 2) 0.71 (0.46 to 1.11) 1.10 (0.86 to 1.41)
 COPD (stage 3) 0.84 (0.57 to 1.23) 0.98 (0.77 to 1.24)
 COPD (stage 4) 0.54 (0.36 to 0.80) 0.75 (0.56 to 0.99)
Cancer treatments‡:
 Surgery 0.63 (0.58 to 0.69) 0.62 (0.58 to 0.67)
 Chemotherapy (stage 1) 1.42 (0.96 to 2.11) 0.93 (0.69 to 1.27)
 Chemotherapy (stage 2) 0.94 (0.78 to 1.12) 0.96 (0.85 to 1.10)
 Chemotherapy (stage 3) 0.69 (0.60 to 0.79) 0.69 (0.62 to 0.76)
 Chemotherapy (stage4) 0.51 (0.44 to 0.60) 0.53 (0.45 to 0.61)
CVD=cardiovascular disease; COPD=chronic obstructive pulmonary disease.
*Scores range between −7 (most affluent) and 11 (most deprived). Adjusted hazard ratio is per 5 unit increase.
†In people without chemotherapy and without CVD and without COPD at the mean age.
‡Adjusted hazard ratio compared with patients without this characteristic. Model for women includes terms for 
age (two fractional polynomial terms, age2 and age2ln(age)) and body mass index (two fractional polynomial 
terms, bmi−2 and bmi−2ln(bmi)). The model for men includes terms for age (two fractional polynomial terms, age 
and ageln(age)) and body mass index (two fractional polynomial terms, bmi−2 and bmi−2ln(bmi)). In men and 
women there were interactions between age and cancer stage, chemotherapy and cancer stage, CVD and cancer 
stage, and COPD and cancer stage. In women there was an interaction between age and aspirin use.
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cause mortality for patients prescribed aspirin at 
 diagnosis of colorectal cancer is consistent with studies 
from Norway and the Netherlands.20 21  Similarly, the 
23-29% reduced mortality among those prescribed 
statins at diagnosis is similar to that reported in a Dan-
ish study.19  The observed and relative net survival rates 
overall and by cancer stage are comparable to those 
reported elsewhere.14 38  For example, the relative net 
five year survival in the Public Health England (PHE) 
validation cohort was 51.2% and the conditional value 
was 71.1% after one year. Coleman et  al reported 
 corresponding values for England (2005-07) of 53.7% 
and 71.8%.14
We found some evidence of a beneficial effect of 
chemotherapy for patients with stages 3 and 4 dis-
ease, with reductions in colorectal cancer mortality 
of between 32% and 49%, which is broadly consistent 
with observational studies47  and meta-analyses of 
clinical trials.48  However, we found no clear evidence 
of a beneficial effect of chemotherapy for patients 
with stages 1 and 2 disease, although the numbers of 
patients receiving treatment were relatively small 
and our study was an observational one rather than a 
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randomised controlled clinical trial so subject to 
residual  confounding. However, our model could 
also be used to risk stratify patients recruited to clin-
ical trials, as has been proposed by Weiser et al for 
similar US based algorithms.6 For example, if higher 
risk groups can be identified, then the sample size 
needed to show a defined benefit could be reduced. 
This could be useful for trials of chemotherapy in 
patients with stage 1 and 2 disease where the benefit 
of chemotherapy is less certain.
Methodological considerations
The statistical methods we have used to derive and 
validate these models are similar to those for other 
risk prediction tools derived from the QResearch data-
base, the strengths and limitations of which have 
been discussed in detail.11 49  In summary, key 
strengths include cohort size, duration of follow-up, 
representativeness, and lack of selection, recall, and 
respondent bias. UK general practices have good lev-
els of accuracy and completeness in recording clinical 
diagnoses and prescribed drugs.50 The QResearch 
database has comprehensive linked cancer and mor-
tality records for virtually all patients and is therefore 
likely to have picked up most cases of colorectal can-
cer and related deaths, thereby minimising ascertain-
ment bias.
We decided to present separate models for men 
and women in our protocol since there were likely to 
be important differences in baseline characteristics 
between the sexes. Our analysis showed differences 
for tumour location (women were more likely to have 
colon cancer than men), uptake of chemotherapy 
and radiotherapy (which was lower in women than 
men), and baseline characteristics (men were more 
likely to smoke, have cardiovascular disease or dia-
betes, and be prescribed aspirin and statins at base-
line). We also found that in women a family history 
of bowel cancer was associated with improved sur-
vival, but this was less so in men. Women with a fam-
ily history of bowel cancer tended to be more affluent 
and also to receive a diagnosis at an earlier stage 
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than women without a family history of bowel can-
cer (table 2 in the web appendix). A possible expla-
nation for these findings may be that women with a 
family history are more aware of red flag symptoms 
and present sooner to their general practitioner and 
are referred more quickly. However, we did include 
both deprivation and cancer stage in our multivari-
ate model.
We undertook two validations, one using a sepa-
rate set of practices and patients contributing to QRe-
search and the other using patients not registered 
with QResearch practices but included on the PHE 
cancer registry. The results of both validations were 
similar, suggesting that the results are likely to be 
generalisable to the population of England. The QRe-
search validation cohort included all the variables 
for men and women used to derive the scores (age, 
body mass index, Townsend score, cancer stage, can-
cer grade, colorectal surgery, family history, raised 
platelet count, abnormal liver function test result, 
statin use, aspirin use,  cardiovascular disease, 
 diabetes, renal disease, and chronic obstructive pul-
monary disease). The fully external NCRAS cohort 
was limited to the following variables: age, cancer 
grade, cancer age, Townsend score, colorectal sur-
gery, and chemotherapy. This may explain why the 
performance was marginally worse in the NCRAS val-
idation cohort (table 6).
Other limitations of our study include the lack of 
formal adjudication of diagnoses, although the accu-
racy of cancer diagnoses is likely to be good given the 
development and utility of the underlying NCRAS 
dataset and its use for national statistics, as well as 
for multiple international research studies.14 38  Our 
primary outcome was death from all causes and we 
are confident that the date of death will be reliable 
since we have used national death certification infor-
mation. Our secondary outcome was death from col-
orectal cancer and this may be susceptible to 
misclassification bias since not all patients will have 
a post-mortem examination. Hence it is possible that 
some patients died of colorectal cancer but had 
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another cause of death recorded and vice versa, 
which could lead to some bias in estimates of cancer 
specific survival.51
There is also potential for bias for predictor vari-
ables owing to missing data for cancer stage, cancer 
grade, smoking status, and body mass index, although 
this was addressed using multiple imputation. Dates 
of colorectal surgery and chemotherapy were unavail-
able on our subset of the NCRAS dataset, other than 
whether they occurred within 12 months of the date of 
diagnosis. This could lead to a survival bias,32 33 mak-
ing colorectal surgery appear to be unduly effective, 
although our additional landmark analysis suggests 
this is likely to be marginal. Other potential variables 
that we have not incorporated include the timeliness 
of treatments and the availability of surveillance lower 
endoscopy examinations. Geographical accessibility 
of medical service providers may also impact on regu-
lar treatment and surveillance of patients with col-
orectal cancer.
While we have derived and validated the equations 
using English datasets, the equations could apply 
internationally by using alternative deprivation 
scores relevant to the setting. Alternatively the post-
code (and hence deprivation scores) can be omitted 
in the web calculator in which case a value of zero 
will be assumed in the calculations. The result of this 
will be to overestimate survival among deprived 
patients and underestimate it for more affluent 
patients. Local validation should be done to ensure 
good calibration and discrimination in the applicable 
population.
Conclusions
We have developed and validated new risk prediction 
equations to quantify overall and cancer specific sur-
vival of patients with colorectal cancer, taking 
account of an individual’s clinical and demographic 
characteristics. A more individualised approach to 
prognosis will help improve the accuracy of informa-
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tion for patients and hence decision making. It could 
also assist with informing follow-up schedules.
A web calculator to calculate estimates of absolute survival can 
be accessed at http://qcancer.org/colorectal-survival/index.php/. 
Open source software is also available for download.
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